Short interest in West Pharmaceutical Services (NYSE:WST) increased significantly by 33.4% as of January 30th, reaching 2,560,146 shares, representing about 3.6% of its shares sold short. This rise in bearish positioning occurred despite the company reporting a strong Q4 earnings beat and issuing bullish FY 2026 guidance, driven by robust demand for its High-Value Product (HVP) components and progress with its SmartDose system. Analysts currently hold a consensus “Buy” rating for WST with an average price target of $314.56.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
West Pharmaceutical Services, Inc. (NYSE:WST) Sees Significant Increase in Short Interest
Short interest in West Pharmaceutical Services (NYSE:WST) increased significantly by 33.4% as of January 30th, reaching 2,560,146 shares, representing about 3.6% of its shares sold short. This rise in bearish positioning occurred despite the company reporting a strong Q4 earnings beat and issuing bullish FY 2026 guidance, driven by robust demand for its High-Value Product (HVP) components and progress with its SmartDose system. Analysts currently hold a consensus “Buy” rating for WST with an average price target of $314.56.